(IN BRIEF) Diavantis, a Dutch company focused on supporting individuals with type 2 diabetes, has been awarded an EFRO grant to develop an innovative app aimed at guiding patients toward a medication-free life. The project, which leverages AI and IoT technology, is led in collaboration with Dr. Elisabeth Wilhelm from the University of Groningen.
(PRESS RELEASE) GRONINGEN, 22-Feb-2025 — /EuropaWire/ — Diavantis, a Dutch organization dedicated to improving the lives of individuals with type 2 diabetes, has received an EFRO subsidy to develop a pioneering mobile application designed to help patients manage their condition without medication. Dr. Elisabeth Wilhelm, an assistant professor in the Engineering and Technology Institute (ENTEG) at the University of Groningen’s Faculty of Science and Engineering, is a key collaborator in this ambitious project.
With the support of the EFRO grant, Diavantis and its partners will create an app that integrates cutting-edge AI and IoT technology to analyze real-time health data. This will allow for the provision of personalized recommendations on vital lifestyle factors such as nutrition, physical activity, sleep, and stress management.
“The rapid rise in type 2 diabetes is placing immense strain on healthcare systems worldwide,” explained Boudewijn Baks, CEO of Diavantis. “This app empowers individuals to take control of their health, reducing reliance on medication. Not only does this benefit patients directly, but it also helps make healthcare more sustainable and ensures that primary care remains accessible for everyone.”
At ENTEG, Dr. Wilhelm is overseeing the scientific validation of the app’s development. A postdoctoral researcher will work on refining the algorithms that will drive the app’s functionalities, focusing on machine learning for real-time data analysis and developing explainable AI techniques for handling time-series data.
“Health-related lifestyle interventions demand applications that are not only effective but also trustworthy and reliable,” said Dr. Wilhelm. “This project presents several scientific challenges, particularly in terms of analyzing sparse data in real time and ensuring the AI’s interpretability for medical purposes.”
The collaborative effort is poised to offer a transformative tool for diabetes management, potentially changing the way patients interact with their health and providing a sustainable approach to tackling the type 2 diabetes epidemic.
For further details on the project and Diavantis’ mission, visit www.diavantis.nl.
———-
First published in this link of EuropaWIRE.
